Clinical efficacy of Atezolizumab/Bevacizumab combined with TACE in treating BCLC stage C hepatocellular carcinoma

BackgroundThe prognosis of advanced primary liver cancer [Barcelona Clinic Liver Cancer (BCLC) stage C] remains poor. Although atezolizumab plus bevacizumab (Ate/Bev) is a standard treatment, the potential of intensifying this regimen into a triple therapy by adding local intervention is unclear.Aim...

Descripción completa

Detalles Bibliográficos

Autores principales:	Lei Yuan, Xiao-Hong Yang, Zhi-Li Ma, Ning Fan, Gen-Shu Wang, Yan-Ling Zhu
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2026-03-01
Colección:	Frontiers in Oncology
Materias:	atezolizumab BCLC stage C bevacizumab hepatocellular carcinoma (HCC) neutrophil-to-lymphocyte ratio (NLR)
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1744076/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!